Pharmacological treatment of behavioural problems in dementia

Australian Prescriber

Volumn 28, Issue 3, 2005, Pages

  Byrne, Gerard J ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antidepressants; Antiepileptics; Antipsychotics

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DIURETIC AGENT; DONEPEZIL; ESCITALOPRAM; GALANTAMINE; HALOPERIDOL; MOCLOBEMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AGGRESSION; AGITATION; AKATHISIA; ANXIETY DISORDER; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONFUSION; DEMENTIA; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; HYPONATREMIA; LOW DRUG DOSE; MEDICAL EXAMINATION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PSYCHOSIS; REVIEW;

EID: 20444396219     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2005.052     Document Type: Review

References (12)

1. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-14.
2. Opie J, Rosewarne R, O'Connor DW.The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J Psychiatry 1999;33:789-99.
3. Bird M, Llewellyn-Jones R, Smithers H, Korten A. Psychosocial approaches to challenging behaviour in dementia: A controlled trial. Canberra: Commonwealth Department of Health and Ageing. 2002. http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/ageing-publicat-psychsoc.htm [cited 2005 May 10]
4. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-43.
5. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57:968-76.
6. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002852. DOI: 10.1002/14651858.CD002852.
7. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-70.
8. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395.
9. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161:1113-5.
10. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al.Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737-46.
11. Fourlanos S, Greenberg P. Managing drug-induced hyponatraemia in adults. Aust Prescr 2003;26:114-17.
12. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54-61.